Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) is a disabling chronic disease of
still unknown origin and complex pathophysiology. The disease affects mainly female patients,
with a female to male ratio of about 9 to 1. Prevalence ranges from 52 to 500/100,000
in females and 8 to 41/100,000 in males. The diagnosis of IC/BPS is mainly hampered
by the lack of appropriate biomarkers and, therefore, extensive clinical examinations are
required to exclude “confusable” diseases [1]. In consequence, most patients experience
several years of ineffective treatments of various urinary tract symptoms often associated
with, but by themselves not characteristic of, IC/BPS. Unequivocal diagnosis of IC/BPS
is the prerequisite to find more effective therapeutic approaches. Therefore, more specific
biomarkers are needed to facilitate IC/BPS diagnosis and to stratify patients for treatment
at earlier stages of the disease. In this Special Issue, we gathered reviews and original work
elucidating the current developments in IC/BPS biomarker research.
| Identifer | oai:union.ndltd.org:DRESDEN/oai:qucosa:de:qucosa:87866 |
| Date | 02 November 2023 |
| Creators | Neuhaus, Jochen, Gonsior, Andreas, Berndt-Paetz, Mandy |
| Publisher | MDPI |
| Source Sets | Hochschulschriftenserver (HSSS) der SLUB Dresden |
| Language | English |
| Detected Language | English |
| Type | info:eu-repo/semantics/publishedVersion, doc-type:article, info:eu-repo/semantics/article, doc-type:Text |
| Rights | info:eu-repo/semantics/openAccess |
| Relation | 1689 |
Page generated in 0.0021 seconds